Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Victory Square Technologies Reports Q3 2025 Financial Results & Provides Corporate Update

By The Northwire Desk — AI Analysis Dec 01, 2025 · 22:29 VST · 0.64 Victory Square Technologies Inc.
VST · Price

Executive Summary

  • Victory Square Technologies reported Q3 2025 Adjusted Revenue of $12.83 M (GAAP $10.52 M) and Adjusted EBITDA of $1.26 M, with cash & marketable securities of $25.91 M at quarter‑end.
  • Hydreight Technologies, the flagship digital‑health subsidiary, delivered a fourth consecutive profitable quarter, more than doubled year‑over‑year revenues, and held $18.64 M in cash supporting national expansion.
  • The Company announced ongoing initiatives across its five platform verticals (digital health, biotech, pet wellness, climate tech, immersive tech), including a $10 M Digital Health & Longevity Accelerator, preclinical work on oral insulin, a new $10 M venture fund for pet‑health startups, and expanded XR health IP development.

Key Details

  • Financial Highlights – Q3 2025 (Three months ended Sep 30, 2025)
  • Adjusted Revenue: $12.83 M
  • GAAP Revenue: $10.52 M
  • Gross Margin: $2.33 M
  • Adjusted EBITDA: $1.26 M

  • Cash & Marketable Securities: $25.91 M

  • Financial Highlights – Nine months ended Sep 30, 2025

  • Adjusted Revenue: $26.71 M

  • GAAP Revenue: $20.44 M

  • Hydreight Technologies (Digital Health)

  • Year‑over‑year revenue more than doubled vs. Q3 2024.
  • Fourth consecutive profitable quarter.
  • Internal forecast of ≈1.3 M product orders for FY 2025.
  • 1,100+ licenses sold across multiple categories.
  • Cash balance at quarter‑end: $18.64 M.

  • Operates a nationwide clinical network covering all 50 U.S. states.

  • Digital Health & Longevity Accelerator – Launched Jan 2025 with $10 M capital to incubate DTC health companies on the VSDHOne platform (focus areas: biomarkers, tele‑pharmacy, dermatology, GLP‑1, TRT, longevity).

  • Insu Therapeutics (Biotech)

  • Ongoing preclinical work on oral insulin tablet.

  • Pursuing FDA 505(b)(2) pathway; first‑in‑human studies targeted for 2026 pending regulatory review.

  • Pawsible Ventures (Pet Health)

  • Launched a $10 M venture fund and studio to support 15–20 pet‑health companies over three years (software, diagnostics, AI tools, supplements).

  • XR Immersive Tech – Expanding health‑related IP: digital twins for metabolic tracking, 3D biomarker visualization, immersive patient education, virtual onboarding for weight‑loss/hormone programs.

  • SafeTest Diagnósticos (Brazil) – Continuing expansion in Brazil’s $15 B diagnostics market with at‑home testing and tele‑health services.

  • Capital Recycling & Allocation

  • Recent disposals: AI fintech tools to Yocale.ai; BlockX to Edge Total Intelligence.

  • Normal Course Issuer Bid (NCIB) announced Sep 22, 2025 – up to 5,000,000 common shares may be repurchased.

  • Outlook & Priorities (Q4 2025 / 2026)

  • Continue supporting Hydreight/VSDHOne platform growth.
  • Advance Insu’s oral insulin program.
  • Deploy Pawsible fund and studio initiatives.
  • Further develop XR health‑tech tools.
  • Ongoing NCIB activity and selective capital recycling.

Notable Quotes

  • “Q3 was another quarter of focused execution across our portfolio… These developments reinforce our long-term strategy and the core verticals where we see significant opportunity for value creation.” – Shafin Diamond Tejani, CEO & Chairman, Victory Square Technologies Inc.
  • “We remain focused on execution within each platform… Our goal is to build long‑term, sustainable value by supporting companies aligned with our core sectors.” – Shafin Diamond Tejani

All forward‑looking statements are subject to risks and uncertainties; actual results may differ materially.

Read the original news release →

More from Victory Square Technologies Inc.

Jun 02, 2026 · 00:03

Victory Square Q1 Revenue Hits Guidance Floor as Hydreight Scales and Insu Advances to Phase II

Earnings May 01, 2026 · 00:14

Hydreight Revenue Guidance Confirmed, But Execution Risk Remains on 4x Growth Target

Earnings Apr 23, 2026 · 08:00

Pawsible Ventures Cohort Launch Validates Victory Square Diversification Strategy as Hydreight Scales

Other Mar 09, 2026 · 08:00

Hydreight Announces Normal Course Issuer Bid

Other Feb 18, 2026 · 16:16

Victory Square Provides Corporate Update on Healthcare Infrastructure Strategy and Portfolio Developments

Production / Operations Feb 02, 2026 · 08:00

Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

Other